{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:49:21Z","timestamp":1778543361096,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":4824,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1093\/annonc\/mdl148","type":"journal-article","created":{"date-parts":[[2006,9,27]],"date-time":"2006-09-27T11:52:55Z","timestamp":1159357975000},"page":"1592-1597","source":"Crossref","is-referenced-by-count":37,"title":["Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG\/ADO study"],"prefix":"10.1016","volume":"17","author":[{"given":"D.","family":"Schadendorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Thoelke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kreissig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Linse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Trefzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Tilgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl148_bb0010","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","article-title":"Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials","volume":"4","author":"Eigentler","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0015","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/sonc.2002.35247","article-title":"The treatment of brain metastases from malignant melanoma","volume":"29","author":"Douglas","year":"2002","journal-title":"Sem Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/sonc.2002.35246","article-title":"Brain metastases in melanoma: a European perspective","volume":"29","author":"Cattell","year":"2002","journal-title":"Sem Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"key":"10.1093\/annonc\/mdl148_bb0030","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5","article-title":"Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases","volume":"66","author":"Jacquillat","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl148_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00008390-200302000-00016","article-title":"A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma","volume":"13","author":"Mornex","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdl148_bb0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbacine in the treatment of patients with advanced metastatic malignant melanoma","volume":"16","author":"Middelton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0045","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1200\/JCO.2005.01.1551","article-title":"Temozolomide in combination with interferon alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized phase III multicenter study of the Dermatologic Cooperative Oncology Group (DeCOG)","volume":"23","author":"Kaufmann","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0050","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl148_bb0055","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1200\/JCO.2005.03.145","article-title":"Current management of brain metastases, with a focus on systemic options","volume":"23","author":"Langer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0060","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2002.04.140","article-title":"Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases","volume":"20","author":"Antonadou","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1008354323167","article-title":"Hellenic Cooperative Oncology Group. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases","volume":"1","author":"Christodoulou","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00432-002-0323-8","article-title":"Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group","volume":"128","author":"Margolin","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00008390-200204000-00011","article-title":"Effect of temozolomide on central nervous system relapse in patients with advanced melanoma","volume":"12","author":"Paul","year":"2002","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdl148_bb0080","doi-asserted-by":"crossref","first-page":"8992","DOI":"10.1200\/JCO.2005.02.5791","article-title":"Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma","volume":"23","author":"Weber","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl148_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdl148_bb0095","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials","volume":"4","author":"Gaspar","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdl148_bb0100","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.1997.371","article-title":"Cerebral metastases of cutaneous melanoma","volume":"76","author":"Gupta","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl148_bb0105","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0110","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.COC.0000020963.71379.FE","article-title":"Selection of patients with melanoma brain metastases for aggressive treatment","volume":"26","author":"Harrison","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0360-3016(99)00416-2","article-title":"Prognostic factors in brain metastases: should patients be selected for agressive treatment according to recursive partitioning analysis (RPA) classes?","volume":"46","author":"Nieder","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdl148_bb0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.bjc.6602018","article-title":"A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma","volume":"91","author":"Morris","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl148_bb0125","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","article-title":"Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study","volume":"22","author":"Agarwala","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(01)00489-2","article-title":"Current and future developments in the use of temozolomide for the treatment of brain tumours","volume":"2","author":"Stupp","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdl148_bb0135","article-title":"Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer","author":"Siena","year":"2003","journal-title":"ASCO"},{"key":"10.1093\/annonc\/mdl148_bb0140","article-title":"A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma","author":"Atkins","year":"2005","journal-title":"ASCO"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419473195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419473195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/10\/1592\/649009\/mdl148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:47:01Z","timestamp":1582199221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419473195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0923753419473195"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl148","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}